Imunon (IMNN) Cash from Financing Activities (2010 - 2026)
Imunon's (IMNN) quarterly Cash from Financing Activities came in at -$1813.0 in Q1 2026, down 101.72% YoY from $105692.0 in Q1 2025, and down 100.03% on a QoQ basis from $7.2 million in Q4 2025.
Imunon (IMNN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Imunon (IMNN) has 17 years of Cash from Financing Activities data on file, last reported at -$1813.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 101.72% year-over-year to -$1813.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 7949.22% YoY) and the FY2025 annual result came in at $17.1 million, up 88.57% from the prior year.
- Cash from Financing Activities fell to -$1813.0 in Q1 2026, from $7.2 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $7.2 million in Q4 2025 to a low of -$6.2 million in Q2 2023.
- A 5-year average of $1.2 million and a median of $91978.0 in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 44730700.0% in 2022, down 669.51% in 2022.
- Tracing IMNN's Cash from Financing Activities over 5 years: stood at $447308.0 in 2022, then tumbled by 93.24% to $30248.0 in 2023, then slumped by 110.83% to -$3277.0 in 2024, then soared by 219533.02% to $7.2 million in 2025, then sank by 100.03% to -$1813.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$1813.0 (Q1 2026), $7.2 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | 10.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.16 Mn |
| Jun 30, 2026 | 10.16 Mn |
| Mar 31, 2026 | -1,813.00 |
| Mar 31, 2026 | -1,813.00 |
| Dec 31, 2025 | 7.19 Mn |
| Dec 31, 2025 | 7.19 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Sep 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | 4.83 Mn |
| Jun 30, 2025 | 4.83 Mn |
| Mar 31, 2025 | 105,692.00 |
| Mar 31, 2025 | 105,692.00 |
| Dec 31, 2024 | -3,277.00 |
| Dec 31, 2024 | -3,277.00 |
| Dec 31, 2023 | 30,248.00 |
| Dec 31, 2023 | 30,248.00 |
| Sep 30, 2023 | 78,264.00 |
| Sep 30, 2023 | 78,264.00 |
| Jun 30, 2023 | -6.22 Mn |
| Jun 30, 2023 | -6.22 Mn |